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Summary  
Objective: To analyze the roles of two classes of proteinases, 'aggrecanase', and matrix metalloproteinases (MMPs), 
in chondrodestruction during murine collagen-induced arthritis (CIA). 
Methods: Generation of the 'aggrecanase' neo-epitope (NITEGE~7~), and the MMP neo-epitope (VDIPEN 34~) within 
aggrecan was studied by immunoperoxidase microscopy using specific anti-peptide antibodies in normal and 
stromelysin-1 (SLN-1) deficient knockout mice with CIA. 
Results: High levels of NITEGE 37~ and VDIPEN TM neo-epitopes were observed in foci within CIA paw articular 
cartilage exhibiting depletion of glycosaminoglycans, in advance of significant cartilage erosion. The highest 
concentrations of NITEGE 373 and VDIPEN TM labeling were observed and often co-distributed in the chondrocyte 
pericellular matrix, suggesting that stimulated chondrocytes can synthesize and/or activate both enzymes. Other 
regions of the cartilage frequently exhibited either NITEGE :~73 or VDIPEN "~41 labeling, but not both neo-epitopes 
simultaneously, suggesting that 'aggrecanase' and MMP cleavages of aggrecan may be generated independently. No 
detectable differences were observed in expression or distribution of either neo-epitope in SLN-1 knockout versus 
wild-type mice. In addition, in vitro digestion of joint sections with SLN-1 did not alter the expression of cartilage 
NITEGE 37~, while markedly increasing VDIPEN TM labeling. Peripheral nerves and brains of naive mice also exhibited 
intense anti-NITEGE 37~ labeling. 
Conclusions: These data indicate that NITEGE sT:~ and VDIPEN TM aggrecan eo-epitopes are sensitive and specific 
markers of early joint pathology, and are consistent with the hypothesis that SLN-1 does not have 'aggrecanase' 
activity, and that 'aggrecanase' is distinct from the MMPs which cleave aggrecan at the MMP site, 
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I n t roduct ion  
REGULATED aggrecan turnover  is crit ical ly im- 
portant  in connective tissue development, as 
well as in maintenance of connective tissue 
homeostasis.  In diseases such as rheumatoid  
arthr it is  (RA) and osteoarthr i t is  (OA), there 
appears to be accelerated aggrecan catabol ism 
which ult imately results in complete destruct ion 
of the art icular  carti lage. The enzymes respon- 
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sible for aggrecan turnover  have not yet been 
definitively identified, but several members of the 
matr ix metal loproteinase (MMP) family have been 
impl icated in this process. MMPs have been 
localized in regions of cart i lage degradat ion [1-3] 
and have been shown to be elevated in joint 
fluids [4, 5], serum [6, 7] and cart i lage extracts 
from pat ients with OA [8]. 
Using a combinat ion of N-terminal sequence 
analysis and immunodetect ion with highly specific 
anti-peptide antibodies, two major catabol ic sites 
within the interglobular  domain of aggrecan have 
been identified: Asn341-Phe 342, a MMP site [9-12], 
and Glu37LAla 374, an 'aggrecanase'  site [12-16]. 
Several  MMPs have been shown to cleave at the 
Asn341-Phe 342 site including interst it ial  col lagenase 
(MMP-1), gelat inase A (MMP-2), stromelysin 
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(MMP-3), matrilysin (MMP-7), neutrophil col- 
lagenase (MMP-8), and gelatinase B (MMP-9) 
[9-11, 17, 18]. However, MMP-8 is the only enzyme 
shown to cleave at the Glu 37;~ Ala ~74 site [10, 18, 19]; 
it was recently detected in both normal and 
osteoarthritic chondrocytes [20-22[. Although it 
is currently unclear whether 'aggrecanase' is
a member of the MMP family, 'aggrecanase'- 
mediated release of aggrecan from cartilage 
explants can be blocked with MMP inhibitors 
[23]. Both 'aggrecanase' and MMP-generated 
fragments are found in cartilage from patients 
undergoing joint replacement for OA or RA, as 
well as in cartilage from individuals and animals 
with no known history of overt joint disease 
[24 28]. Furthermore, 'aggrecanase'-generated 
fragments are the predominant aggrecan frag- 
ment in joint fluids of patients with OA, RA 
or traumatic joint injury [4, 14]. Together, these 
data indicate that both 'aggrecanase' and the 
classical MMPs are active within articular 
cartilage and play a role in aggrecan turnover 
during normal cartilage remodeling, as well as 
in the uncontrolled aggrecan degradation i OA 
and RA. 
Several animal models have been used to study 
inflammatory arthritis, including the murine type 
II collagen-induced arthritis model (CIA) [29, 30], 
the proteoglycan-induced mouse arthritis model 
[31], and the streptococcal cell wall arthritis model 
iri rats [32]. We have previously demonstrated that 
the MMP-generated aggrecan fragment terminat- 
ing in VDIPEN TM is present in areas of articular 
cartilage degeneration in these models ([33], 
unpublished observations). The appearance of this 
neo-epitope is consistent with cleavage of aggre- 
can by MMPs between Ash TM and Phe 342 in these 
inflammatory arthritis models. Antibodies to the 
'aggrecanase'-generated ggrecan fragment termi- 
nating in the neo-epitope NITEGE aT~ have. also 
been developed. They require the C-terminal Glu aTa 
for optimal recognition, and do not recognize the 
NITEGE ~73 sequence when it is part of the 
aggrecan core protein [12]. The objective of the 
investigation reported herein is to determine if the 
'aggrecanase'-generated neo-epitope NITEGE 37:3 is 
induced in articular cartilage in CIA, and to 
compare its distribution with that of the MMP-gen- 
erated VDIPEN 34~ neo-epitope. These studies 
focused on mouse CIA because of the many 
features of this model in common with human 
inflammatory arthritis, and because it has enabled 
us to evaluate the distribution of these neo-epi- 
topes in animals where one of the major MMPs, 
stromelysind, has been knocked-out (SLN-1 ko 
mice) [34, 35]. 
Methods 
ANIMALS 
CIA was induced in 8-10-week-old B10.RIII 
mice by immunization with a single intradermal 
injection of highly purified porcine type II collagen 
in complete Freund's adjuvant, as previously 
described [30], followed by subcutaneous adminis- 
tration of 327 ng human rIL-l~3 on days 13, 14, 
and 15. SLN-1 knockout (ko) and wild-type (wt) 
mice [34] were back-crossed twice to B10.RIII 
mice to generate N2 B10.RIII SLN-1 ko and N2 
B10.RIII wt back-cross mice. Animals were geno- 
typed by Southern analysis to determine which 
animals carried the targeted SLN-1 allele as 
escribed [35]. N2 B10.RIII SLN-1 ko mice and N2 
B10.RIII wt mice were immunized identically, as 
described above. Non-immunized mice of each 
genotype served as naive controls. Animals were 
euthanized 21 days later, when many exhibited 
stage 2 clinical symptoms (swelling of >2 digits, 
and/or the carpus and tarsus). Paws were removed 
proximal to the tarsus or carpus, embedded in OCT 
medium (Miles, Naperville, IL, U.S.A.), frozen in 
liquid nitrogen, and stored at -70~ Animals were 
maintained in American Association of Laboratory 
Animal Care-accredited facilities, and the exper-" 
iments were approved by the Merck Research 
Laboratory Institutional Animal Care and Use 
Committee in accordance with NIH and USDA 
guidelines. 
IMMUNOPEROXIDASE MICROSCOPY 
Sagittal 5 ~m cryosections were cut with carbide 
knives on a model OTF Bright Cryotome (Hacker 
Instruments, Inc. Fairfield NJ, U.S.A.) equipped 
with a cryostat frozen sectioning aid (In- 
strumedics, Inc., Teaneck, NJ, U.S.A.). Frozen 
sections were mounted on glass slides, treated with 
protease-free chondroitinase ABC (0.02 U, 30 mM 
Na acetate, 0.1 M Tris-HC1, pH 8.0; Seigagaku 
America, Rockville, MD, U.S.A.) as previously 
described [33], and mildly fixed for 20 min with 
Nakane solution (periodate/lysine/paraformalde- 
hyde) [36]. NITEGE 373 neo-epitopes were labeled 
with rabbit anti-NITEGE 3~3 IgG [12] that was 
purified on a YPLPRNITEGE-peptide affinity 
resin. VDIPEN TM neo-epitopes were also labeled 
on adjacent cryosections with rabbit anti- 
VDIPEN TM IgG affinity-purified as previously 
described [33]. Bound antibodies were detected 
on the frozen sections via immunoperoxidase 
microscopy using the ABC technique (Elite kit; 
Vector Labs., Inc., Burlingame, CA, U.S.A.). 
Peroxidase reaction product was developed with 
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a glucose oxidase/DAB/nickel method [37] with 
1% orange G used as a counterstain. To control 
for specificity, the primary anti-NITEGE :~7:~ IgG 
(2 ~tg/ml) was incubated with 50 pg/ml of either the 
neo-epitope peptide (H2N-YPLPRNITEGE-COOH) 
or a peptide spanning the 'aggrecanase' cleavage 
site (H2N-YPLPRNITEGEARGS-COOH) prior to 
immunoperoxidase labeling. Similar controls were 
also conducted for the VDIPEN TM antibody [33]. To 
investigate whether the anti-NITEGE IgG is 
capable of interacting with a possibly related 
epitope present at an 'aggrecanase-l ike' cleavage 
site in brevican [38-40], similar competit ion 
experiments were conducted with the following 
peptides: H2N-LKLPQEAVESE-COOH, and H2N- 
LKLPQEAVESESRGA-COOH. Peptides were syn- 
thesized on an Applied Biosystems 430A peptide 
synthesizer and purified by reversed-phase high 
performance liquid chromatography (HPLC) on a 
Waters C18 Deltapak column. All peptides were 
>95% pure by reversed-phase HPLC, and the 
structure of each was confirmed by electrospray 
ionization mass spectroscopy. Pre-immune rabbit 
IgG was used as an additional negative control. To 
determine the effect of SLN-1 on expression of the 
NITEGE 373 neo-epitope, unfixed cryosections were 
digested with activated recombinant human SLN-1 
(rhSLN-1) (100~tg~/ml in 150mm NaC1, 25mM 
Tris-HC1, t0 mM CaC12, 0.05% Brij-35, pH 7.4) for 
30min at 37~ prior to staining with either 
anti-NITEGE 373 'IgG or anti-VDIPEN :34~ IgG. The 
carti lage glycosaminoglycan (GAG) content of 
adjacent sections was also determined by toluidine 
blue staining as previously described [41]. Photo- 
micrographs were made at 10-25• with a Leitz 
Vario Orthomat microscope. 
Results 
DETECTION OF ANT I -N ITEGE ~v3 LABELING IN 
CONTROL TISSUE 
High concentrat ions of anti-NITEGE 37:~ labeling 
were localized in peripheral nerves [Fig. l(a),(c)], 
and at the insertion sites of tendons [Fig. l(b)] 
in either naive [Fig. l(a),(b)], or IL-l[3-treated 
[Fig, 1(c)] control B10.RIII mice. Pre-incubation 
of the anti-NITEGE 373 IgG (2 pg/ml) with 50 ~g/ml 
YPLPRNITEGE 37:~, a peptide corresponding to the 
C-terminus of the 'aggrecanase'-generated aggre- 
can G1 fragment completely abolished this stain- 
ing [Fig. l(d)]. In comparison, the control peptide 
a 84 b 
d 
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Fro. 1. The 'aggrecanase' cleavage site (NITEGE ~73) is present in control B10.RIII mice. (a) Anti-NITEGE 373 is localized 
in the endoneurium ofperipheral nerves exhibiting the characteristic snake-fence distribution of nerve fibers (arrows) 
in the basal reticular dermis and among muscle fibers, and (b) in the proximal Achilles' tendon (arrowheads) of 
non-boosted naive control mice. (c) Binding of NITEGE :~7:~ IgG to peripheral nerves occurs in the presence of the 
spanning peptide YPLPRNITEGEARGS, but is inhibited by the C-terminal peptide YPLPRNITEGE (d) in adjacent 
cryosections of IL-l[~-boosted but unimmunized control mice. Bar for (a)-(d)= 100 ~m. 
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FIG. 2. Small NITEGE:373-positive foci are localized in the peripheral AC of naive control B10.RIII mice. Sequential  
cryosections of a tarsus stained with hematoxylin and eosin (a), toluidine blue (b), anti-NITEGE 373 IgG (c), and 
anti-VDIPEN TM IgG (d). (a) Central (arrowhead) and peripheral (arrow) regions of the AC are intact (S = synovium). 
(b) Central AC zone (arrowhead) is rich in GAGs, while the peripheral region (arrow) is GAG-depleted. (c) Peripheral 
AC exhibits focal NITEGE .7:~ staining (arrow), coincident with the GAG-depleted region shown in (b), whereas the 
central region (arrowhead) is unlabeled. (d) No VDIPEN TM staining is detectable throughout the AC of an adjacent 
section. Bar for (a)-(d) = 100 ~LM. 
spann ing  this c leavage site (YPLPRNITEGEAR-  
GS; 50 gg/ml) did not  inhibit  label ing [Fig. 1(c)]. 
Ant i -VDIPEN TM sta in ing was cons istent ly  absent  
from these t issue sites (data not  shown). These 
results confirm that  our  ant i -N ITEGE 37~ IgG 
specif ical ly recognizes the N ITEGE 373 sequence 
when it is presented as a C-terminal  neo-epitope, 
but not  when it is an internal  component  of the 
peptide sequence. In addit ion, foci of N ITEGE a73 
neoepitope label ing were observed at the ar t icu lar  
surfaces of some paw joints in both naive and 
IL-l~3-boosted non- immunized contro l  B10.RII I  
mice. These joints showed no h isto logical  signs of 
damage or inf lammation [Fig. 2(a)], but  sl ight GAG 
deplet ion of the per iphera l  ar t icu lar  cart i lage (AC) 
was occas ional ly  detectable by to lu id ine blue 
sta in ing [Fig. 2(b)]. Small  foci of ant i -N ITEGE a73 
label ing were local ized in the per ice l lu lar  and 
interterr i tor ia l  AC matr ix  [Fig. 2(c)], co inc ident  
with this GAG deplet ion [corresponding arrows in 
Figs 2(b) and (c)]. S l ight s ta in ing was also 
observed sur round ing  chondrocytes  of the adja- 
cent calcif ied cart i lage [Fig. 2(c)]. There was no 
observable ant i -VDIPEN TM sta in ing at these 
NITEGEaT<posit ive foci [Fig. 2(d)]. Ne i ther  neo- 
epitope was detected in the synov ium (Fig. 2). No 
detectable dif ferences were observed between the 
joints of IL-113-boosted and non-boosted naive 
contro l  B10.RII I  animals.  Simi lar results were also 
obta ined with non- immunized N2 B10.RII I  SLN-1 
Table I 
Capacity of 'aggrecanase' and 'aggrecanase-like' p ptides 
to inhibit anti-NITEGE immunolabeling of peripheral 
nerves and chondrocytes in the naive mouse hind paw* 
Peripheral Peripheral 
Peptides nerves chondrocytes 
LKLPQEAVESE + + + + + + + 
LKLPQEAVESESRGA 0 0 
YPLPRNITEGE + + + + + + + + 
YPLPRNITEGEARGS 0 0 
*Hind paws of untreated 8-week-old BI0.RIlI control mice 
were cryosectioned mid-sagittally, and the NITEGE 373 neo-epitope 
was labeled in the presence of the indicated peptides by 
immunoperoxidase microscopy as described in Methods. Key: 
+ + + = nearly complete inhibition of anti-NITEGE 373 staining; 
+ + + + = total inhibition of anti-NITEGE 3v~ staining; 0 = no 
inhibition of anti-NITEGE 3v3 staining. 
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ko and N2 B10.RIII wt control mice (data not 
shown). 
NITEGE 37:~ IgG LABELS AN 'AGGRECANASE-LIKE'  
NEO-EPITOPE IN BREVICAN 
The intense anti-NITEGE a73 IgG labeling of 
peripheral nerves suggested that this antibody 
might also recognize a related epitope in nerve 
tissue proteoglycans. Additional competition ex- 
periments were therefore conducted to determine 
if the NITEGE 37~ antibody interacts with the 
C-terminal ESE epitope present at an 'aggre- 
canase-like' cleavage site in brevican [38-40]. 
Peptides containing either the native ESE C- 
terminus or the spanning sequence of the brevican 
'aggrecanase-like' site were synthesized. The 
results of these experiments are presented in 
Table I. The brevican 'aggrecanase-like' C-
terminal cleavage peptide LKLPQEAVESE inhib- 
ited the anti-NITEGE a7:3 labeling of chondrocytes 
equally, as well as YPLPRNITEGE, the aggrecan 
blocking peptide. LKLPQEAVESE also inhibited 
the anti-NITEGE '~7:~ staining of peripheral nerves 
nearly as well as YPLPRNITEGE. Alterna- 
tively, the control brevican spanning peptide 
LKLPQEAVESESRGA did not inhibit labeling 
of either chondrocytes or nerves. There was also 
intense anti-NITEGE aT:~ IgG staining in naive 
control mouse brain cryosections, where labeling 
was particularly concentrated in the corpus 
collosum, and in most other myelinated nerve 
tracts (data not shown). 
INDUCTION OF NITEGE aT:~ AND VDIPEN TM 
NEO-EPITOPES IN CIA 
High concentrations of both the NITEGE aTa and 
VDIPEN TM neo-epitopes were induced and local- 
ized in large foci within the AC of tarsal and 
metatarsal joints of B10.RIII mouse paws with 
stage 2 CIA (Fig. 3). The NITEGE aT* neo-epitope 
was particularly concentrated in the pericellular 
matrix of AC chondrocytes [Figs 3(a),(e),(g)]. The 
VDIPEN TM neo-epitope was also localized in the 
pericellular matrix of AC chondrocytes where it 
often appeared to co-distribute with NITEGE aTa 
[corresponding arrows in Figs 3(a) and (b); (e) and 
(f); (g) and (h)]. Both neo-epitopes were induced 
in AC loci exhibiting GAG depletion (indicated 
by reduced toluidine blue staining; data not 
shown), in the absence of erosion of the articular 
surface. In addition to this codistribution, the 
'aggrecanase' and MMP neo-epitopes also exhib- 
ited complementary staining patterns. The MMP 
neo-epitope was heavily concentrated at the 
articular surface and in the interterritorial matrix 
of the AC [Figs 3(b),(f),(h)]. NITEGE aT~ labeling 
was usually not detectable at the AC surface, but 
tended to be localized around chondrocytes in 
the deeper zones of the AC adjacent o the calci- 
fled cartilage [Figs 3(a),(e),(g)]. Some deeper 
chondrocytes were associated with both 
NITEGE 373 and VDIPEN TM staining, while others 
were NITEGEaT:~-positive and VDIPENa4~-negative 
[Figs 3(e)-(h)]. 
EXPRESSION OF THE NITEGE 373 EPITOPE IS 
UNAFFECTED BY SLN ACTIVITY 
To investigate the possible effects of SLN-1 
activity on induction of the NITEGE 373 epitope, 
cryosections of B10.RIII mouse paws with clinical 
stage 2 CIA were exhaustively digested with 
rhSLN-1 before to labeling the anti-NITEGE 373 or 
VDIPEN TM antibodies. Pre-digestion with exogen- 
ous SLN-1 did not alter the distribution of 
endogenous NITEGE 373 staining, and did not 
decrease or increase the intensity of NITEGE 373 
labeling [Figs 4(a) and (b)]. In contrast, pre- 
incubation of adjacent sections with SLN-1 
produced a massive increase in VDIPEN TM labeling 
in the AC [Figs 4(c) and (d)]. These data suggest 
that exogenous SLN can digest aggrecan within 
the cartilage matrix, but the 'aggrecanase'- 
generated G1 fragment appears resistant o this 
degradation. 
APPEARANCE OF THE 'AGGRECANASE' AND MMP 
CLEAVAGE SITES IN SLN-1  KO MICE wITH C IA  
High local concentrations of both the NITEGE aT~ 
and VDIPEN TM neo-epitopes were also codis- 
tributed in the pericellutar matrix of AC chondro- 
cytes in the paws of N2 B10.RIII SLN-1 ko mice 
with stage 2 CIA (data not shown). In addition, 
these neo-epitopes often exhibited non-coincident 
staining patterns at several AC foci in these N2 
B10.RIII SLN-1 ko mice (Fig. 5), and in control 
B10.RIII animals exhibiting stage 2 CIA (data 
not shown). While both neo-epitopes were present 
in some metatarsal joints, other similar joints 
stained for either one or the other neo-epitope 
[Figs 5(a) and (b), (d) and (e)], in joints where 
the AC exhibited GAG depletion [Fig. 5(c) and 
(f)]. The relative abundance of these coincident 
and non-coincident patterns of N ITEGE av~ and 
VDIPEN TM neo-epitope distribution in N2 BI0.RIII 
SLN-I ko mice, N2 BI0.RIII wt mice, and BI0.RI]I 
mice with stage 2 CIA is shown in Table If. All N2 
Bt0.RIII SLN-1 ko, B10.RIII, and N2 B10.RIII wt 
mice with CIA exhibited either one or the other 
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FIG. 3. Both the 'aggrecanase' and MMP neo-epitopes may be co-distributed in the AC of B10.RIII mice with CIA. 
Adjacent cryosections of t ibio-tarsal joints of paws with stage 2 CIA stained for NITEGE ~73 [(a), (c), (e), (g)] and 
VDIPEN 341 [(b), (d), (f), (h)]. (a) and (b) Both neo-epitopes may be co-localized at loci in certain AC regions, while other 
AC zones exhibit complementary distributions of these cleavage sites. (a) Intense NITEGE 373 labeling is present in the 
pericel lular matrix (arrowheads). Long arrows indicate chondrocytes that are also positive for VDIPEN 341 (b). Some 
regions with intense NITEGE 3w staining exhibit reduced VDIPEN 341 labeling [crosses; see (b)]. (b) VDIPEN TM staining 
is localized at the AC surface (short arrows), and in chondrocyte pericel lular and interterr i tor ial  matrices 
(arrowheads). Some foci with intense VDIPEN ~41 labeling exhibit l itt le NITEGE 373 stain [asterisks; see (a)]. (c) and (d) 
Foci exhibiting both NITEGE 373 (c) and VDIPEN 341 (d) labeling. (e) and (f) Higher magnification of the lower portions 
of (c) and (d) show NITEG E 37~ (e) localized in the deep zone of the AC (arrowheads), while VDIPEN TM (f) is concentrated 
in the superficial zone of the AC. Corresponding arrows depict hondrocytes positive for NITEGE 3n and VDIPEN3% 
(g) and (h) Enlargement of the upper regions of (c) and (d). NITEGE 373 (g) and VDIPEN TM (h) are localized in the same 
pericel lular and interterr i tor ial  matrices (arrows), but NITEGE 37~ labeling appears more widespread. Bar for (a) and 
(b)-- 20 pM; bar for (c) and (d) = 100 pM; bar for (e)-(h) = 50 ~tM. 
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FIG. 4. SLN-1 digestion does not remove existing NITEGE 3n labeling, and does not induce additional NITEGE 37:~ 
neo-epitope. Adjacent cryosections of a B10.RIII mouse tarsometatarsal joint with stage 2 CIA were stained for 
NITEGE 37a without (a) or with (b) SLN-1 predigestion, or for VDIPEN TM without (c) or with (d) SLN-1 predigestion. 
Pretreatment of the cryosection with SLN-1 induces intense VDIPEN TM labeling throughout the AC (d), but has no 
detectable effect on NITEGE 373 staining (b). Bar for (a)-(d) = 100 gM. 
neo-epitope localized in the AC in some of their 
affected joints. In addition, at least 75% of the mice 
examined regardless of genotype showed a coinci- 
dent distribution of the NITEGE 37~ and VDIPEN TM 
neo-epitopes in the AC pericellular matrix in other 
affected joints. 
Discuss ion  
We have detected both the NITEGE :~73 ('aggre- 
canase') and VDIPEN TM (MMP) neo-epitopes in 
the AC of inflamed paws of mice with CIA via 
immunoperoxidase microscopy. The highest con- 
centrations of immuno-specific labeling for both 
neo-epitopes were localized in the pericellular 
matrix of AC chondrocytes in paws with a clinical 
score of 2 or higher. This labeling appeared in 
portions of the AC exhibiting early stages of 
disease (as evidenced by local depletion of GAGs), 
before significant erosion of the AC occurred. 
Staining for the NITEGE ;~73 ('aggrecanase') neo- 
epitope of aggrecan was performed using affinity- 
purified antibody and shown to be specific since: (1) 
it was inhibited by a peptide with NITEGE 373 
C-terminus, but not with a peptide spanning the 
'aggrecanase' cleavage site; (2) it stained only a 
specific proteoglycan fragment of the appropriate 
molecular weight extracted from human OA AC 
[26]; and (3) it required the entire NITEGE 373 
sequence, including the free COO- of the C- 
terminal Glu for optimal recognition in a radio- 
immunoassay [12]. The NITEGE 373 antibody was 
also found to interact with a closely related 
'aggrecanase-like' C-terminal ESE cleavage site 
of brevican [40], but not with ESE within the 
control peptide spanning this cleavage site. The 
immunospecificity of the VDIPEN TM antibody has 
been previously reported [33]. 
This is the first time that the  NITEGE ~73 
C-terminus has been identified and immunolocal- 
ized in AC of arthritic animals. Previous descrip- 
tions of the 'aggrecanase'-generated neo-epitope 
:~74ARGSV were derived from N-terminal sequenc- 
ing of aggrecan fragments in culture media from 
AC explants stimulated with either IL-I~ or 
retinoic acid [15, 16], and synovial fluids from 
patients with traumatic joint injury, OA, or RA 
[13, 14]. More recently, aggrecan fragments with 
the NITEGE 373 C-terminus were detected in 
normal, OA, and RA human AC [25, 27]. To- 
gether these data are consistent with the pro- 
posal that 'aggrecanase' is an endoproteinase 
and that AC aggrecan fragments are not the 
result of proteolysis of the entire hyaluronan- 
binding G1 domain. In addition, these results 
indicate that aggrecan N-termini presenting either 
the NITEGE 373 or VDIPEN TM neo-epitopes remain 
bound within the cartilage matrix following 
cleavage. 
The patterns of VDIPEN TM staining are con- 
sistent with MMP activity being secreted by 
both AC chondrocytes, ynoviocytes, and inflam- 
matory cells from the synovial cavity and pannus. 
It appears that chondrocytes are the source of 
'aggrecanase' in AC based on its localization in 
the pericellular matrix deep within the AC, and 
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Fro. 5. NITEGE :~3 and VDIPEN TM expression may occur independent ly  in the AC of N2 B10.RIII SLN-1 ko mice with 
CIA. Consecutive sections of a t ib iotarsal  jo int  (a), (b), (c) and a tarsometatarsal  jo int  (d), (e), (f) from an N2 B10.RIII 
SLN-1 ko mouse with stage 2 CIA, were stained with ant i -NITEGE 37a IgG (a), (d), ant i -VDIPEN TM IgG (b), (e), or 
toluidine blue (c), (f). Intense NITEGE :~73 sta in ing (a) with l itt le VDIPEN TM induct ion (b) occurs in the GAG-depleted 
(c) tarsal  AC (arrowheads). Alternately,  maximal VDIPEN TM label ing (e) may occur without detectable NITEGE 37:~ 
expression (d) in GAG-depleted (f) tarsometatarsal  AC. Bar for (a)-(f)= 100 ~LM. 
Table II 
Distribution of N ITEGE 373 and VDIPEN TM neo-epitopes in mice with CIA* 
Animals Coincident NITEGE aTa Non-coincident NITEGE 37:~ 
Genotype sampled and VDIPEN TM label ing and VDIPEN TM label ing 
B10.RIII 17 13 17 
N2 B10.RIII 
SLN-1 ko 5 4 5 
N2 B10.RIII wt 2 2 2 
*Hind paws of mice exhibiting clinical stage 2 CIA (18 21 days after immunization) were cryosectioned 
mid-sagittally, and the NITEGE 37~ and VDIPEN 34j neo-epitopes detected in the sectioned articular cartilage of 
various joints by immunoperoxidase microscopy. 
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the paucity of anti-NITEGE 373 staining in the 
more superficial zones of the AC. Although both 
neo-epitopes were often co-localized surrounding 
chondrocytes at some foci within the AC, 
NITEGE 373 and VDIPEN TM were also localized 
independently of each other in other regions of the 
AC. Likewise, NITEGE37:~-positive G1 aggrecan 
fragments were generated in retinoic acid- 
stimulated rat chondrosarcoma cells, without 
evidence of cleavage at the VDIPEN TM site [12]. 
This differential expression of the NITEGE 373 and 
VDIPEN TM neo-epitopes suggests that under some 
conditions, aggrecan molecules that are cleaved 
by 'aggrecanase' are not cleaved by classical 
MMPs, and vice versa. These results also imply 
that 'aggrecanase' activity is independent of 
MMP activity, and further suggest hat MMPs 
and 'aggrecanase' may be regulated differently. 
This is not only evident in inflamed arthritic 
tissues, but also in the extracellular matrix of 
control tissues. Anti-NITEGE :~73 (but not anti- 
VDIPEN TM) labeling was detected in the peripheral 
AC, tendons, peripheral nerves, and brain of 
control mice. Similar results have previously 
been reported in the bovine system, in which 
'aggrecanase'-generated G1 fragments were found 
in extracts of fetal and calf menisci and liga- 
ment, but not within growth plate or articular 
cartilage [42]. It appears that anti-NITEGE 373 is 
an early and sensitive marker of aggrecan or 
brevican catabolism in normal connective tissue. 
Together, these data suggest hat 'aggrecanase' 
may be involved in normal proteoglycan metab- 
olism whereas MMPs, in combination with 
'aggrecanase', may play a more dominant role in 
aggrecan catabolism in the AC of the inflamed 
joint. 
The localization of strikingly high concentra- 
tons of anti-NITEGE :~73 IgG labeling in control 
B10.RIII mouse peripheral nerves and brain is a 
surprising observation. The nature of this inter- 
action was investigated by performing compe- 
tition experiments with the C-terminal and 
spanning peptides of an 'aggrecanase-like' cleav- 
age site observed in brevican, an abundant 
aggrecan-like chondroitin sulfate proteoglycan 
present in adult brain [38 40]. The C-terminal 
brevican neo-epitope peptide LKLPQEAVESE 
was found to effectively inhibit the anti- 
NITEGE 373 immunolabeling of both peripheral 
nerves and chondrocytes in cryosections of the 
naive mouse paw, while the peptide spanning this 
cleavage site did not inhibit labeling. These 
observations uggest that in addition to the 
aggrecan -EGE site, the anti-NITEGE 373 IgG 
recognizes a closely related -ESE 'aggrecanase- 
like' neo-epitope in brevican. The generation of 
this brevican cleavage site appears to have a 
physiological basis, and presumably is not due to 
proteolytic cleavage which may occur during 
biochemical isolation of brevican [39], because 
the neo-epitope is abundant in freshly frozen, 
well-preserved peripheral nerves and brain. Ag- 
gregating proteoglycans of the aggrecan/versican 
family are abundant in the extracellular matrix 
of brain and peripheral nerves [39, 43, 44], and 
are believed to be involved in regeneration of 
the peripheral nervous system [45, 46]. The local- 
ization of anti-NITEGE 373 IgG in peripheral 
nerves and brain suggests that an 'aggrecanase- 
like' enzyme may regulate the catabolism of 
brevican, and possibly aggrecan or other aggre- 
can-like molecules, in normal nerves and during 
neural tissue remodeling. 
Interestingly, when SLN-l-treated mouse paw 
sections were stained with the neo-epitope anti- 
bodies, there was no change in the intensity 
of staining for the 'aggrecanase'-generated 
NITEGE 37~ neo-epitope, while VDIPEN TM (MMP- 
generated neo-epitope) staining clearly increased. 
These data suggest hat 'aggrecanase'-generated 
G1 neo-epitopes remain bound within the AC 
matrix even after subsequent exposure to SLN-1. 
This is a surprising result since theoretically, 
SLN-1 treatment should have converted the 
G1-NITEGE 373 fragments into GI-VDIPEN 341 
species with a consequent loss of NITEGE 37:~ 
staining. Since treatment with SLN-l-generated 
a clear increase in VDIPEN TM labeling within 
the AC, G1 cleavage must be occurring under 
the conditions of the experiment. Therefore, SLN-1 
probably cleaved the 'aggrecanase'-generated GI- 
NITEGE 373 fragments, leaving the cleaved C- 
terminal NITEGE 373 fragments bound within the 
AC matrix, possibly by non-covalent associations 
with other matrix molecules through keratan 
sulfate side chains. The additional observation 
that treatment of the cartilage with exogenous 
SLN-1 did not increase the level of NITEGE 3~3 
labeling, suggests trongly that SLN-1 does not 
cleave at the 'aggrecanase' site, as shown 
previously with purified aggrecan [26]. 
It has previously been shown that SLN-1 cleaves 
aggrecan between Asn34'-Phe ~2 in vitro, generating 
an aggrecan fragment erminating in VDIPEN TM 
[47]. In contrast, SLN-1 does not cleave aggrecan 
at the 'aggrecanase' site under similar conditions 
[26]. To determine if SLN-1 was the only enzyme 
cleaving aggrecan at the MMP site in vivo, 
expression of the VDIPEN 341 neo-epitope was 
examined by immunolocalization in SLN-1 ko mice 
with CIA [34, 35]. No detectable differences in AC 
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loss, proteoglycan staining, or induction of 
aggrecan cleavage at VDIPEN TM were observed 
among B10.R111, N2 B10.R111 wt, and N2 B10.R111 
SLN-1 ko mice with CIA [34, 35]. The current  study 
addresses the question of whether deletion of 
SLN-1 gene influences aggrecan cleavage at the 
'aggrecanase'  site during CIA. There were no 
observable differences in the staining patterns or 
expression levels of N ITEGE 373 within the AC of 
the N2 B10.Rl11 SLN-1 ko mice compared with 
N2 B10.Rl l l  wt siblings and B10.RIII animals 
expressing SLN-1. These data, together with the 
observat ion that  digestion of mouse paw cryosec- 
tions with rhSLN-1 does not induce addit ional 
N ITEGE 373 labeling in AC, suggest that  SLN-1 
does not have 'aggrecanase'  activity, and does 
not seem to influence the expression level of 
N ITEGE 37s in CIA. Furthermore,  it appears that 
addit ional MMPs (possibly in combinat ion with 
SLN-1), cleave aggrecan at the MMP site in the 
murine CIA model [35]. It  has previously been 
shown that a number of MMPs can cleave 
aggrecan at the MMP site [9-11, 17, 19, 26], and 
that  some of these enzymes are upregulated in 
paws of N2 B10.R111 SLN-1 ko animals with 
CIA [34, 35]. Therefore, in a complicated inflam- 
matory process such as that  seen in CIA, it is 
probable that mult iple MMPs in addit ion to 
'aggrecanase'  may be contr ibut ing to aggrecan 
cleavage. 
The induction of both 'aggrecanase' -  and 
MMP-generated aggrecan neo-epitopes appears 
to be a sensitive and speci.fic indicator of early 
AC pathology. Taken together with recent data 
localizing NITEGE 37~ and VDIPEN 34I in damaged 
regions of human RA and OA AC [24-27], our 
results suggest hat  the N ITEGE 373 and VDIPEN TM 
neo-epitopes are re levant  markers  of aggrecan 
catabol ism in arthr i t ic  disease. The data presented 
here are consistent with the proposal that  
'aggrecanase'  is a different enzyme than the MMPs 
which cleave aggrecan at the MMP site, and that  
both activit ies are differential ly regulated. Unfor- 
tunately,  the data do not resolve the question of 
which enzyme cleaves the aggrecan molecule first 
during the chondrodestruct ive process [26]. Using 
these neo-epitope antibodies in well-defined time- 
course experiments may help to answer this 
question. In any case it seems that  both 'aggre- 
canase',  as well as addit ional 'classical '  MMPs, 
are involved in aggrecan cleavage during CIA. 
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